Literature DB >> 2327649

Cheyne-Stokes respiration presenting as sleep apnea syndrome. Clinical and polysomnographic features.

W T Dowdell1, S Javaheri, W McGinnis.   

Abstract

This study reports polysomnographic features of five patients with Cheyne-Stokes respiration (CSR). They were referred for evaluation of presumptive sleep apnea syndrome on the basis of history and physical examination, but were found to have predominantly CSR on all-night sleep study. On the initial polysomnographic study, CSR comprised 47 to 86% of all disordered-breathing events. Cheyne-Stokes respiration resulted in considerable oxyhemoglobin desaturation (mean baseline saturation was 95 +/- 4 +/- SD, and lowest saturation was 76 +/- 8). More than one-half of all CSR events resulted in awakenings or arousals. Evidence of upper airway obstruction was noted in the majority of CSR events in three of five patients. Four patients were treated with theophylline; one who refused drug therapy was treated with nasal continuous positive airway pressure (CPAP). Comparison of sleep studies before and after therapy showed a significant decrease in the CSR index (29 +/- 11 versus 2 +/- 2) and in the maximal oxyhemoglobin desaturation associated with CSR (13 +/- 5 versus 3 +/- 2), and an improvement in lowest O2 saturation associated with CSR (76 +/- 8 versus 91 +/- 4). Total disruptions in sleep architecture per hour of sleep improved significantly with therapy (46 +/- 21 versus 20 +/- 8). We conclude that the clinical presentation of CSR can be indistinguishable from that of the "traditional" sleep apnea hypopnea syndrome and can result in major oxyhemoglobin desaturation and sleep fragmentation. Theophylline results in considerable improvement in the disordered breathing of CSR during sleep.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327649     DOI: 10.1164/ajrccm/141.4_Pt_1.871

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  17 in total

1.  Treatment of central sleep apnoea in congestive heart failure with nasal ventilation.

Authors:  G N Willson; I Wilcox; A J Piper; W E Flynn; R R Grunstein; C E Sullivan
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 2.  Sleep in congestive heart failure.

Authors:  Bhavneesh Sharma; Robert Owens; Atul Malhotra
Journal:  Med Clin North Am       Date:  2010-05       Impact factor: 5.456

3.  Prevalence and treatment of breathing disorders during sleep in patients with heart failure.

Authors:  Shahrokh Javaheri; Laura Wexler
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-08

4.  In patients with heart failure the burden of central sleep apnea increases in the late sleep hours.

Authors:  Shahrokh Javaheri; Scott W McKane; Nathan Cameron; Robin E Germany; Atul Malhotra
Journal:  Sleep       Date:  2019-01-01       Impact factor: 5.849

5.  Lung function, hypoxic and hypercapnic ventilatory responses, and respiratory muscle strength in normal subjects taking oral theophylline.

Authors:  S Javaheri; L Guerra
Journal:  Thorax       Date:  1990-10       Impact factor: 9.139

Review 6.  Flow-regulatory function of upper airway in health and disease: a unified pathogenetic view of sleep-disordered breathing.

Authors:  S S Park
Journal:  Lung       Date:  1993       Impact factor: 2.584

Review 7.  Cheyne-stokes respiration in patients with heart failure.

Authors:  Laila AlDabal; Ahmed S BaHammam
Journal:  Lung       Date:  2009-12-03       Impact factor: 2.584

8.  Sleep dysfunction in heart failure.

Authors:  Shahrokh Javaheri
Journal:  Curr Treat Options Neurol       Date:  2008-09       Impact factor: 3.598

9.  Obstructive apnoeas in Duchenne muscular dystrophy.

Authors:  Y Khan; J Z Heckmatt
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

Review 10.  Treatment of sleep disordered breathing in congestive heart failure.

Authors:  Samuel L Krachman; Gilbert E D'Alonzo; Irene Permut; Wissam Chatila
Journal:  Heart Fail Rev       Date:  2008-07-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.